Loading...
XKRX004310
Market cap65mUSD
Dec 24, Last price  
3,630.00KRW
1D
-1.09%
1Q
-20.22%
Jan 2017
-23.48%
Name

Hyundai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:004310 chart
P/E
15.50
P/S
0.52
EPS
234.23
Div Yield, %
0.87%
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
6.69%
Revenues
180.76b
+11.11%
111,663,468,000120,520,284,000122,879,077,000111,860,453,000113,046,193,000102,253,367,360108,135,474,310107,836,679,060109,829,319,990120,021,835,020130,480,291,100130,790,769,420134,649,736,200132,965,511,610139,802,753,090162,690,046,040180,762,658,997
Net income
6.12b
P
9,736,198,0003,475,226,0001,670,588,0002,968,064,000989,545,000-4,849,874,0501,414,880,0501,468,256,1201,593,782,2801,260,887,3601,458,346,750-2,106,347,7901,212,848,4802,187,063,540-3,173,176,160-164,583,3106,121,759,550
CFO
-4.55b
L
6,202,364,000-1,098,603,000-6,889,088,0002,678,234,0007,847,499,000-2,697,301,9107,951,085,7603,470,131,760-2,848,169,700-2,746,972,140-1,981,203,1203,399,507,8405,713,714,11010,804,339,3405,132,208,83011,623,766,830-4,545,282,670
Dividend
Mar 05, 202435 KRW/sh

Profile

Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical equipment in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and eye vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. The company was founded in 1965 and is headquartered in Seoul, South Korea.
URL
http://www.hyundaipharm.co.kr/
IPO date
Jun 28, 1978
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
180,762,659
11.11%
162,690,046
16.37%
Cost of revenue
148,559,560
130,404,709
Unusual Expense (Income)
NOPBT
32,203,099
32,285,337
NOPBT Margin
17.82%
19.84%
Operating Taxes
1,912,563
5,834,291
Tax Rate
5.94%
18.07%
NOPAT
30,290,535
26,451,046
Net income
6,121,760
-3,819.55%
(164,583)
-94.81%
Dividends
(826,200)
(836,054)
Dividend yield
0.77%
0.62%
Proceeds from repurchase of equity
(3,803,529)
(11,526,314)
BB yield
3.55%
8.55%
Debt
Debt current
38,624,266
29,351,849
Long-term debt
1,785,558
10,532,615
Deferred revenue
132,258
342,000
Other long-term liabilities
342,000
(231,482)
Net debt
13,842,548
(1,446,462)
Cash flow
Cash from operating activities
(4,545,283)
11,623,767
CAPEX
(6,104,432)
(6,583,939)
Cash from investing activities
(3,088,416)
(9,991,002)
Cash from financing activities
(6,429,027)
7,005,290
FCF
(3,083,012)
42,704,429
Balance
Cash
18,643,420
34,534,227
Long term investments
7,923,856
6,796,699
Excess cash
17,529,143
33,196,424
Stockholders' equity
131,784,646
129,874,931
Invested Capital
114,995,189
91,226,560
ROIC
29.38%
27.62%
ROCE
23.66%
25.20%
EV
Common stock shares outstanding
27,110
27,812
Price
3,950.00
-18.47%
4,845.00
-1.72%
Market cap
107,083,220
-20.53%
134,751,204
-1.96%
EV
120,925,768
133,304,742
EBITDA
35,503,469
35,582,597
EV/EBITDA
3.41
3.75
Interest
1,907,332
1,160,811
Interest/NOPBT
5.92%
3.60%